Prostaglandin E1: Electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease

John C. Somberg*, V. Yelamanchi, Janos Molnar, Michael Aschermann, P. J.L.M. Bernink, Avi Caspi, Alon Marmor, Babeth Rabinowitz, Leonardo Reisin, Witold Ruzyllo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Prostaglandin E1 (PGE1), the active ingredient of the drug alprostadil-α-cyclodextrin, has been effective in mitigating the clinical manifestations of peripheral arterial occlusive disease (PAOD). PGE1 often is administered to patients with the potential for developing serious arrhythmias, presenting potential safety hazards if the drug caused or potentiated arrhythmias. However, PGE1 has antiadrenergic properties and, theoretically, might have an antiarrhythmic action. Therefore, the effect of PGE1 on frequency and severity of atrial and ventricular arrhythmias was evaluated from 48-hour electrocardiographic recordings in patients receiving PGE1 therapy for severe PAOD. No significant effects on arrhythmia frequency or severity, and no evidence of proarrhythmia, was apparent after PGE1 administration.

Original languageEnglish
Pages (from-to)401-404
Number of pages4
JournalAmerican Journal of Therapeutics
Volume4
Issue number11-12
DOIs
StatePublished - 1997

Keywords

  • Peripheral arterial occlusive disease
  • Proarrhythmia
  • Prostaglandin E

Fingerprint

Dive into the research topics of 'Prostaglandin E1: Electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease'. Together they form a unique fingerprint.

Cite this